7.1600
23-5月-25 13:45:00
15 分の遅延
株式
-0.0300
-0.42%
本日の幅
7.0200 - 7.1800
ISIN
N/A
ソース
NASDAQ
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
15 5 2025 05:00:00 提供 Nasdaq GlobeNewswire
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
08 5 2025 04:00:00 提供 Nasdaq GlobeNewswire
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
08 2 2024 13:05:00 提供 Nasdaq GlobeNewswire